Erratum: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer (Journal of Clinical Investigation (2013) 123, 7 (3183) DOI:10.1172/JCI65385);Tumor vegf:vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Journal of Clinical Investigation

Volumn 123, Issue 4, 2013, Pages 1732-1740

  Sampurna Chatterjee, ^a   Heukamp, Lukas C ^b   Siobal, Maike ^a   Schöttle, Jakob ^a   Wieczorek, Caroline ^a   Peifer, Martin ^a   Frasca, Davide ^b   Koker, Mirjam ^a   König, Katharina ^b   Meder, Lydia ^b   Rauh, Daniel ^c   Buettner, Reinhard ^b   Wolf, Jürgen ^b   Brekken, Rolf A ^d   Neumaier, Bernd ^a   Christofori, Gerhard ^e   Thomas, Roman K ^a,b,c   Ullrich, Roland T ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; VANDETANIB; VASCULOTROPIN C;

AMINO ACID TRANSPORT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE AMPLIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; POSITIVE FEEDBACK; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84875846289     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70810     Document Type: Erratum

References (22)

1. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009; 19(5):329-337.
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389-395.
3. Lee TH, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007;4(6):e186.
4. Chung GG, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer. 2006; 106(8):1677-1684.
5. Silva SR, et al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer. 2011;128(5):1045-1056.
6. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010; 140(2):268-279.
7. Yang F, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011; 71(16):5512-5521.
8. Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645-4655.
9. Pao W, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.
10. Shields AF, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4(11):1334-1336.
11. Blencke S, et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol. 2004; 11(5):691-701.
12. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin Cancer Biol. 2005;15(4):254-266.
13. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer Cell. 2003;4(2):147-158.
14. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273(37):23629-23632.
15. Vasudevan KM, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009;16(1):21-32.
16. Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 1998;58(9):1952-1959.
17. Laking GR, Price PM. Positron emission tomographic imaging of angiogenesis and vascular function. Br J Radiol. 2003;1:S50-S59.
18. O'Reilly KE, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500-1508.
19. Takahashi O, et al. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res. 2012; 18(6):1641-1654.
20. Duvel K, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39(2):171-183.
21. Sos ML, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest. 2009;119(6):1727-1740.
22. Ullrich R, et al. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008; 14(7):2049-2055.